Post Profile






Adding oxidative stress to FLT3 inhibition proves promising combination against AML

(University of Colorado Anschutz Medical Campus) A University of Colorado Cancer Center study published today in the Proceedings of the National Academy of Sciences demonstrates the promise of adding drugs that increase oxidative stress to FLT3 inhibition, potentially paving the way for combination therapy directed at the disease.
read more

share

Related Posts


Macular Degeneration Insight Identifies Promising Drugs to Prevent Vision Loss

Health : Newswise Medical News

In a study published this week in the Proceedings of the National Academy of Sciences, a University of Wisconsin-Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration, a common co...

Cancer-Fighting Cocktail Demonstrates Promising Results as New Treatment for Advanced Cervical Cancer

Health : Newswise Medical News

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer res...

Removal Of A Tiny RNA Molecule Can Inhibit Cancer Growth

Health : Medical News Today

Research from the University of Louisville published in the Proceedings of the National Academy of Sciences indicates the removal of a tiny RNA molecule in mice suppresses carcinogenic tumor formation. The study appears in the journ...

BSD Medical Announces Publication Of Study Showing Hyperthermia Increases Effectiveness Of Other Cancer Treatments By Preventing Repair Of Tumor Cells

Health : Medical News Today

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences ...

"Dramatic" Early Phase 1 Results for AG-120 in IDH1 Mutated AML

Health : Newswise Medical News

University of Colorado Cancer Center study shows "extremely promising" early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in ...

Comments


Copyright © 2016 Regator, LLC